Point72 Asset Management
ALNY icon

Point72 Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Point72 Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.85M Sell
5,600
-800
-13% -$272K ﹤0.01% 2361
2025
Q4 		$2.54M Buy
+6,400
New +$2.83M ﹤0.01% 2327
2017
Q4 		– Sell
-100,000
Closed -$11.7M – 894
2017
Q3 		$11.7M Buy
+100,000
New +$8.54M 0.05% 369

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management's ALNY Position: Q4 2025 in Review

Point72 Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 6,197 shares — an estimated $2.74M sold.

Point72 Asset Management first reported a position in ALNY in Q3 2014 and held it in 19 quarters. The position peaked at $134M in Q2 2018. 848 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

  • Point72 Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Point72 Asset Management sold 6,197 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $2.74M.
  • Point72 Asset Management first reported a position in Alnylam Pharmaceuticals in Q3 2014 and held it in 19 quarters.
  • Point72 Asset Management's Alnylam Pharmaceuticals position peaked at $134M in Q2 2018.
  • 848 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Point72 Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.